URL has been copied successfully!
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) shares are rising in extended trading Monday after the company announced positive interim results for one of its Phase 3 trials.
- Vertex Pharmaceuticals stock is trading in a tight range. What’s next for VRTX stock?
Vertex Reports Positive Results For All Endpoints
Vertex announced positive data from a pre-specified week 36 interim analysis of its ongoing phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy.
Povetacicept is an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines.
The trial met its primary objective, achieving a 52% reduction …
Please follow us:
